Clinical

Dataset Information

0

CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy


ABSTRACT: This is a non-profit phase II, randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy, compared to cetuximab alone, in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients (according to liquid biopsy at baseline). Patients have been treated in first line with chemotherapy in combination with cetuximab and have had a clinical benefit (complete or partial response) from treatment.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2710266 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2733983 | ecrin-mdr-crc
| 2352516 | ecrin-mdr-crc
2017-12-20 | GSE93192 | GEO
2024-09-01 | E-MTAB-13368 | biostudies-arrayexpress
2020-05-22 | GSE150970 | GEO
| PRJNA713424 | ENA
| 2402930 | ecrin-mdr-crc
| 2538194 | ecrin-mdr-crc
| S-EPMC9272566 | biostudies-literature
| 2256554 | ecrin-mdr-crc